Researchers in the Netherlands successfully applied mitochondrial base editing using DdCBE technology to correct pathogenic mitochondrial DNA mutations in patient-derived models. This advancement overcomes previous hurdles of accessing mitochondrial genomes and may lay groundwork for developing gene therapies targeting mitochondrial disorders, which have been historically difficult to treat.